AI assistant
Sending…
Terns Pharmaceuticals, Inc. — Director's Dealing 2025
Feb 4, 2025
32559_dirs_2025-02-03_a3d7966c-5726-496c-a8a4-03c1bbe2d356.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2025-02-01
Reporting Person: KINDLER JEFFREY B (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-02-01 | Stock Option (Right to Buy) | $4.46 | A | 10657.00 | Acquired | 2035-01-31 | Common Stock (10657.00) | Direct |
Footnotes
F1: This option was issued pursuant to the Issuer's Non-Employee Director Compensation Policy, under which the Reporting Person elected to receive this option in lieu of the Reporting Person's cash retainer fee of $40,000 for 2025.
F2: The option will vest as to 1/12th of the total shares subject thereto on each monthly anniversary measured from January 1, 2025, such that 100% of the shares subject to the option will be fully vested on January 1, 2026.